The Insulin Resistance Intervention after Stroke Trial A randomized, placebo-controlled trial of pioglitazone, compared with placebo, for prevention of stroke and myocardial infarction after ischemic stroke and transient ischemic attack

Trial Profile

The Insulin Resistance Intervention after Stroke Trial A randomized, placebo-controlled trial of pioglitazone, compared with placebo, for prevention of stroke and myocardial infarction after ischemic stroke and transient ischemic attack

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Sep 2017

At a glance

  • Drugs Pioglitazone (Primary)
  • Indications Insulin resistance; Myocardial infarction; Stroke
  • Focus Therapeutic Use
  • Acronyms IRIS
  • Most Recent Events

    • 18 Sep 2017 Results published in the JAMA Neurology.
    • 28 Feb 2017 Results of a secondary analysis investigating the effects of pioglitazone on acute coronary syndromes (ACS) (MI and unstable angina) among IRIS participants, published in the Circulation.
    • 24 Feb 2017 Results (N=3707) presented at the 42nd International Stroke Conference.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top